Celsion Presents ThermoDox® Clinical Data At The 2010 Breast Cancer Symposium
Celsion Corporation (Nasdaq: CLSN) announced that interim data from its Phase I/II DIGNITY trial of ThermoDox® in Recurrent Chest Wall (RCW) Breast Cancer were presented at the poster session at the 2010 Breast Cancer Symposium. The abstract provided updated clinical results from the 40 mg/m2 dose cohort...
More... |
All times are GMT -7. The time now is 01:56 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021